

**DPM examination 2018 -Short Answer Question #10 (HE)**

- 10 a) In the context of health technology assessments (HTAs) and economic evaluations, what do you understand by:
- i. Quality-adjusted-life-years (QALYs) (4 marks)
  - ii. Incremental cost effectiveness ratio (ICER)
- b) How does an ICER influence whether an intervention is funded? (1 mark)
- c) Drug Z is an investigational oral medication for lung cancer about to start phase 3 trials. Current standard of care is intravenous chemotherapy. Apart from traditional efficacy and safety data to achieve registration, briefly discuss the types of data you would expect to see collected in the pivotal phase 3 programme that will support the production of robust economic models for future HTA submissions. (5 marks)